{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-166857","form_type":"8-K","ticker":"QTTB","cik":"0001661998","company_name":"Q32 Bio Inc.","filed_at":"2023-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.890726+00:00","generated_at":"2026-06-14T01:17:53.539718+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Homology Medicines shareholders elect two Class II directors and ratify auditor at annual meeting","bullets":["Steven Gillis, Ph.D. elected with 32,246,621 votes for and 2,619,932 withheld; 10,698,943 broker non-votes.","Albert Seymour, Ph.D. elected with 34,681,867 votes for and 184,686 withheld; 10,698,943 broker non-votes.","Ratification of Deloitte & Touche LLP as independent auditor approved: 44,765,597 for, 108,239 against, 691,660 abstained."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-166857","json":"https://secwatch.observer/filing/0001193125-23-166857.json","markdown":"https://secwatch.observer/filing/0001193125-23-166857.md","text":"https://secwatch.observer/filing/0001193125-23-166857.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661998/000119312523166857/0001193125-23-166857-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661998/000119312523166857/d285694d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T01:17:53.539718+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"06f48692a84c461006a70d5777bf0d97e3cb6996","claim":"Q32 Bio Inc. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023 at the 2023-06-14 meeting.","evidence_excerpt":"Item 2 - Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 44,765,597 108,239 691,660 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661998/000119312523166857/0001193125-23-166857-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-14"}],"fact_type":"shareholder_vote"},{"claim_id":"4ec9abe29791deff6e941e34639b49ae0144c644","claim":"Q32 Bio Inc. shareholders approved Election of two Class II Directors to serve until the Company's 2026 Annual Meeting of Stockholders at the 2023-06-14 meeting.","evidence_excerpt":"NOMINEE Votes FOR Votes WITHHELD Broker Non-Votes Steven Gillis, Ph.D. 32,246,621 2,619,932 10,698,943 Albert Seymour, Ph.D. 34,681,867 184,686 10,698,943","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661998/000119312523166857/0001193125-23-166857-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-14"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}